Skip to main content
Premium Trial:

Request an Annual Quote

Matritech Launches New Website; Promotes Sales of FDA-Approved Bladder Cancer Products

NEW YORK, Aug. 13 (GenomeWeb News)- Matritech, a developer of protein-based diagnostics products for early detection of cancer, announced today that it has launched its new website at


Designed by Boston-based Weymouth Design, Matritech's new website provides updated information on the company's products that are in development and on the market, and allows physicians to order Matritech's NMP22 BladderChek Test online.


Matritech's first two products, the NMP22 BladderChek test and NMP22 test kit have been approved by the US Food and Drug Administration for the monitoring and diagnosis of bladder cancer. Aside from developing products for bladder cancer, the company has also used its proteomics technology to discover proteins associated with cervical, prostate, breast and colon cancer.


The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.